Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InspireMD (NSPR) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for InspireMD (NSPR) over the last 4 years, with Q3 2025 value amounting to $73.5 million.

  • InspireMD's Shares Outstanding (Diluted Average) rose 5188.63% to $73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.5 million, marking a year-over-year increase of 5188.63%. This contributed to the annual value of $41.9 million for FY2024, which is 7277.09% up from last year.
  • Latest data reveals that InspireMD reported Shares Outstanding (Diluted Average) of $73.5 million as of Q3 2025, which was up 5188.63% from $51.0 million recorded in Q2 2025.
  • In the past 5 years, InspireMD's Shares Outstanding (Diluted Average) ranged from a high of $73.5 million in Q3 2025 and a low of $7.8 million during Q2 2022
  • For the 4-year period, InspireMD's Shares Outstanding (Diluted Average) averaged around $31.8 million, with its median value being $34.1 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 33356.42% in 2023, then surged by 4215.96% in 2025.
  • InspireMD's Shares Outstanding (Diluted Average) (Quarter) stood at $7.9 million in 2022, then skyrocketed by 208.29% to $24.3 million in 2023, then soared by 72.77% to $41.9 million in 2024, then skyrocketed by 75.22% to $73.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $73.5 million in Q3 2025, compared to $51.0 million in Q2 2025 and $50.0 million in Q1 2025.